美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Tetraphase Pharmaceuticals Inc.

2.20

0.0000

成交量：- -

成交額：- -

市值：1,597.91萬

市盈率：-0.17

高：2.20

開：2.20

低：2.20

收：2.20

52周最高：8.60

52周最低：0.5600

股本：726.32萬

流通股本：503.36萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-13.3067

每股收益(LYR):-22.8513

淨資產收益率：-138.80%

總資產收益率：-51.46%

市淨率：0.58

市盈率(LYR):-0.10

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Tetraphase Pharmaceuticals Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.tphase.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Tetraphase Pharmaceuticals, Inc.依據特拉華州法律於2006年7月7日成立，是一家臨床階段的生物製藥公司，利用其專有的化學技術為嚴重的、威脅生命的、有多種抗藥性的感染病的治療創造新型的抗生素。公司領先的藥品替代物eravacycline是一種完全的合成四環素衍生物，將作為首要的偏方單一治療法發展成一種廣泛的靜脈注射和口服的抗生素，用於治療抗多種藥物感染病的治療，包括革蘭氏陰性感染病。公司最近為患有複雜腹內感染病（cIAI）患者採用靜脈內給藥的方式成功完成了eravacycline階段二的臨床試驗，目前正在進行關鍵性的eravacycline階段三測試。公司期望完成兩項全球性的eravacycline階段三臨床試驗，一項是對cIAI的治療試驗，另一項是對複雜尿路感染餅（cUTI）的治療試驗。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TTPH/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TTPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTPH\",,,,,undefined,":{"symbol":"TTPH","market":"US","secType":"STK","nameCN":"Tetraphase Pharmaceuticals Inc.","latestPrice":2.2,"timestamp":1595966400000,"preClose":2.2,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":5033625,"shares":7263236,"eps":-13.306672,"marketStatus":"退市","change":0,"latestTime":"07-28 16:00:00 EDT","open":2.2,"high":2.2,"low":2.2,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.306672,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1772787600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1363752000000,"exchange":"NASDAQ","adjPreClose":2.2,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTPH\",,,,,undefined,":{"symbol":"TTPH","floatShares":5033625,"roa":"-51.46%","roe":"-138.80%","lyrEps":-22.85132,"shares":7263236,"dividePrice":0,"high":2.2,"amplitude":0,"preClose":2.2,"low":2.2,"week52Low":0.56,"pbRate":"0.58","week52High":8.6,"institutionHeld":0,"latestPrice":2.2,"eps":-13.306672,"divideRate":0,"volume":0,"delay":0,"ttmEps":-13.306672,"open":2.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTPH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-05-07","symbol":"TTPH","fiscalQuarterEnding":"2020/03","expectedEps":-1.63,"name":null,"time":"","type":"earning","dateTimestamp":1588824000000,"reportTimeType":"","actualEps":-1.31},{"market":"US","date":"2020-03-12","symbol":"TTPH","fiscalQuarterEnding":"2019/12","expectedEps":-5.68,"name":null,"time":"","type":"earning","dateTimestamp":1583985600000,"reportTimeType":"","actualEps":null},{"date":"2019-11-12","symbol":"TTPH","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-6.27,"defaultRemindTime":1573592400000,"name":null,"time":"盤後","dateTimestamp":1573534800000,"actualEps":null},{"market":"US","date":"2019-09-27","symbol":"TTPH","type":"split","dateTimestamp":1569556800000,"forFactor":20,"toFactor":1,"ratio":20},{"date":"2019-08-08","symbol":"TTPH","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.38,"defaultRemindTime":1565294400000,"name":null,"time":"盤後","dateTimestamp":1565236800000,"actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTPH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TTPH\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TTPH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TTPH","date":"2020-07-28","current":-0.165331,"percent":0.148148,"low":-0.322562,"twenty":-0.24552,"median":-0.163297,"eighty":-0.111312,"high":-0.068361,"avg":-0.171046,"sd":0.066471,"marketCap":16652545},"quantilePoints":[],"updateTime":1772782727405},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.tphase.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0119},{"period":"3month","weight":-0.0064},{"period":"6month","weight":0.0526},{"period":"1year","weight":0.1685},{"period":"ytd","weight":-0.0009}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Tetraphase Pharmaceuticals, Inc.依據特拉華州法律於2006年7月7日成立，是一家臨床階段的生物製藥公司，利用其專有的化學技術為嚴重的、威脅生命的、有多種抗藥性的感染病的治療創造新型的抗生素。公司領先的藥品替代物eravacycline是一種完全的合成四環素衍生物，將作為首要的偏方單一治療法發展成一種廣泛的靜脈注射和口服的抗生素，用於治療抗多種藥物感染病的治療，包括革蘭氏陰性感染病。公司最近為患有複雜腹內感染病（cIAI）患者採用靜脈內給藥的方式成功完成了eravacycline階段二的臨床試驗，目前正在進行關鍵性的eravacycline階段三測試。公司期望完成兩項全球性的eravacycline階段三臨床試驗，一項是對cIAI的治療試驗，另一項是對複雜尿路感染餅（cUTI）的治療試驗。","exchange":"NASDAQ","name":"Tetraphase Pharmaceuticals Inc.","nameEN":"Tetraphase Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"TTPH\",market:\"US\",,,undefined,":null}}